- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00211237
CAFE Study - Cancer Patient Fracture Evaluation (CAFE)
A Multicenter, Prospective, Randomized, Controlled Study to Compare Balloon Kyphoplasty to Non-surgical Fracture Management in the Treatment of Painful, Acute Vertebral Body Compression Fractures in Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
1. STUDY OBJECTIVES AND ENDPOINTS
1.1. Objectives
The primary objective of this study is to evaluate the safety and effectiveness of balloon kyphoplasty treatment for painful, acute, VCFs as compared to standard non-surgical therapy in patients with cancer.
1.2. Primary Endpoint
The primary endpoint of the study is the improvement in functional status, as measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 month. The primary hypothesis of the study is that the mean improvement will be larger in subjects initially assigned to management with balloon kyphoplasty. Note that all subjects will undergo 12 months of follow-up after initial treatment assignment.
1.3. Secondary Endpoints
The following secondary endpoints will also be examined. Comparisons will be made at each follow-up visit.
Safety:
- Rate of study treatment-related adverse events
- Change in neurological status
Clinical:
- Change in functional status as assessed with Karnofsky Performance Scale
- Change in quality of life as assessed by the SF-36v2™ Health Survey
- Change in back pain, as measured by a 10-point Numerical Rating Scale (NRS)
- Change in back-pain analgesics used
- Change in ambulation status
- Changes in activities of daily living
- Time to treatment failure
Radiographic:
- Change in spinal deformity, defined as the degree of spine angulation as assessed by an independent radiologist at the core laboratory
- Rate of subsequent vertebral body fractures, as assessed by independent radiologists at the core lab
In each case, the study hypothesis is that treatment with balloon kyphoplasty will result in an improvement in clinical or radiographic outcomes compared to baseline and compared to non-surgical treatment, with a preservation of outcomes in long-term follow-up.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Victoria
-
Fitzroy, Victoria, Australia, 3065
- St. Vincent's Hospital
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
-
-
-
-
Brussels, Belgium
- Institut Jules Bordet
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N2T9
- Foothills Hospital
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 2S8
- Toronto Western Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3G 1A4
- Montreal General Hospital
-
-
-
-
-
Berlin, Germany
- Charite Virchow-Klinikum
-
Hannover, Germany
- Medizinische Hochschule
-
-
-
-
-
Budapest, Hungary
- National Center for Spinal Disorders
-
-
-
-
-
Uppsala, Sweden
- Akademiska Sjukhuset
-
-
-
-
-
London, United Kingdom
- Royal London
-
-
-
-
California
-
Escondido, California, United States, 92025
- Valley Radiology Inc., UCSD
-
-
Colorado
-
Boulder, Colorado, United States, 80304
- Boulder Neurosurgical Associates
-
-
Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt Cancer Center
-
-
Maryland
-
Chevy Chase, Maryland, United States, 20815
- Sibley Memorial Hospital
-
Silver Spring, Maryland, United States, 20910
- Greater Oncology Associates
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- University of Utah
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- One to 3 painful (pain on palpation/percussion over fractured vertebral body) VCF(s), T5-L5, with either bone marrow edema imaged by magnetic resonance imaging (MRI) or a fracture imaged by plain radiographs using the method of Genant
Pain NRS score ≥4 on a scale of 0 to 10
- When the patient is newly diagnosed with multiple myeloma, the pain assessment must not be done until after completion of at least one pulse of steroid therapy or one week after the initiation of active multiple myeloma therapy.
- Roland Morris Disability Questionnaire score ≥ 10 on a scale of 0 to 24
- Patients must be at least 21 years old.
- No change in chemotherapy regimen (change in dose(s) permitted) for 1 month prior to enrollment
- No change in chemotherapy regimen (change in dose(s) permitted) planned for at least 1 month following enrollment
- No major surgery to the spine planned for at least 1 month following enrollment
- Life expectancy of ≥ 3 months
- Patient has sufficient mental capacity to comply with the protocol requirements
- Patient has stated availability for all study visits
- Patient is able to understand the risks and benefits of participating in the study and is willing to provide written informed consent.
Exclusion Criteria:
- Patients with primary tumors of the bone (e.g., osteosarcoma) or solitary plasmacytoma at site of the index VCF. Patients with these tumors in anatomic sites other than the index VCF are eligible.
- Concurrent Phase I investigational anti-cancer treatment
- Significant clinical morbidities (aside from the index fracture(s) and cancer) that may potentially interfere with the collection of data concerning pain and function
- VCF morphology deemed unsuitable for balloon kyphoplasty
- Additional non-kyphoplasty surgical treatment is required for the index fracture
- Patients requiring the use of high-dose steroid (≥ 100 mg prednisone or 20 mg dexamethasone per day), intravenous (IV) pain medication, or nerve block to control chronic back pain unrelated to index VCF(s). Patients who receive high-dose steroids for treatment of their cancer (for at least 30 days) are eligible.
- Patients with a platelet count of < 20,000 measured at the time of hospital admission for the procedure
- Spinal cord compression or canal compromise requiring decompression
- Patients with osteoblastic tumors at the site of index VCF. Patients with osteoblastic tumors outside of vertebral levels intended for kyphoplasty may be enrolled.
- Medical/surgical conditions contrary to the balloon kyphoplasty procedure (e.g., in the presence of active or incompletely treated local infection)
- Known allergy to bone cement or contrast medium used in the treatment of study subjects
- MRI contraindication (e.g., cerebral aneurysm clips, pacemaker, implanted biostimulators, cochlear implants, penile prosthesis)
- Positive baseline pregnancy test (for women of child-bearing potential)
- Patients who may require allogeneic bone marrow transplantation during the course of the study.
Other Reasons for Lack of Enrollment:
A. Patient is afraid to have surgery
B. Patient is afraid to have anesthesia
C. Patient/family is not willing to participate in research
D. Patient is not willing to be randomized
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Balloon Kyphoplasty (BKP)
The subjects assigned to this group will undergo the treatment with Balloon kyphoplasty for their painful VCFs.
|
Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
Other Names:
|
Active Comparator: Non Surgical Management
The subjects in this group will undergo the non-operative treatments aimed at alleviation of back pain and restoration of decreased function associated with VCFs.
|
Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Functional Status, as Measured by the Roland-Morris Disability Questionnaire (RDQ) at 1 Month
Time Frame: Baseline and 1 Month
|
The full scale name is the Roland-Morris Disability Questionnaire; it is a validated measure of physical disability due to back pain. The best score is 0 (no disability) and worst is 24 (maximum disability) |
Baseline and 1 Month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Roland-Morris Disability Questionnaire Score
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Roland-Morris Disability Questionnaire (RMDQ) was used to assess the physical disability due to back pain.
The best score is 0 (no disability) and worst is 24 (maximum disability).
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in Functional Status Assessed With the Karnofsky Performance Scale
Time Frame: Baseline and 1 month
|
The Karnofsky Performance Scale rates a patient on an 11-step scale from 0 (dead) to 100 (normal, no complaints, no evidence of disease).
|
Baseline and 1 month
|
Change in Functional Status Assessed With the Karnofsky Performance Scale
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
The Karnofsky Performance Scale rates a patient on an 11-step scale from 0 (dead) to 100 (normal, no complaints, no evidence of disease).
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in Back Pain
Time Frame: Baseline and 1 month
|
Back pain was assessed on a 10-point Numerical Rating Scale (NRS) from 0 (no pain) to 10 (worst possible pain).
|
Baseline and 1 month
|
Change in Back Pain
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
Back pain was assessed on a NRS from 0 (no pain) to 10 (worst possible pain).
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in Quality of Life.
Time Frame: Baseline and 1 month
|
The SF-36 was used to assess quality of life.
The SF-36 results were summarized into two components, a physical component summary score (PCS) (0-100) and a mental component summary score (MCS) (0-100).
The higher the score, the better the quality of life.
|
Baseline and 1 month
|
Change in Quality of Life
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
The SF-36 were used to assess quality of life.
The SF-36 results were summarized into two components, a physical component summary score (PCS) (0-100) and a mental component summary score (MCS) (0-100).
The higher the score, the better the quality of life.
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in Activities of Daily Living - Activities Reduced Due to Back Pain in Previous 2 Weeks
Time Frame: Baseline and 1 month
|
The Activities of Daily Living assessment comprised three questions about the effects of back pain or back problems over the previous 2-week period.
The patient was asked if they had cut down on usual activities, the number of days in which the patient had cut down on usual activities and the number of days that the patient had spent at least half a day in bed because of back pain or back problems.
|
Baseline and 1 month
|
Change in Activities of Daily Living - Activities Reduced Due to Back Pain in Previous 2 Weeks
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
The Activities of Daily Living assessment comprised three questions about the effects of back pain or back problems over the previous 2-week period.
The patient was asked if they had cut down on usual activities, the number of days in which the patient had cut down on usual activities and the number of days that the patient had spent at least half a day in bed because of back pain or back problems.
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in Activities of Daily Living - Number of Days With Reduced Activities Due to Back Pain in Previous 2 Weeks
Time Frame: Baseline and 1 month
|
The Activities of Daily Living assessment comprised three questions about the effects of back pain or back problems over the previous 2-week period.
The patient was asked if they had cut down on usual activities, the number of days in which the patient had cut down on usual activities and the number of days that the patient had spent at least half a day in bed because of back pain or back problems.
|
Baseline and 1 month
|
Change in Activities of Daily Living - Number of Days With Reduced Activities Due to Back Pain in Previous 2 Weeks
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
The Activities of Daily Living assessment comprised three questions about the effects of back pain or back problems over the previous 2-week period.
The patient was asked if they had cut down on usual activities, the number of days in which the patient had cut down on usual activities and the number of days that the patient had spent at least half a day in bed because of back pain or back problems.
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Change in Activities of Daily Living - Number of Days in Bed Due to Back Pain in Previous 2 Weeks
Time Frame: Baseline and 1 month
|
The Activities of Daily Living assessment comprised three questions about the effects of back pain or back problems over the previous 2-week period.
The patient was asked if they had cut down on usual activities, the number of days in which the patient had cut down on usual activities and the number of days that the patient had spent at least half a day in bed because of back pain or back problems.
|
Baseline and 1 month
|
Change in Activities of Daily Living - Number of Days in Bed Due to Back Pain in Previous 2 Weeks
Time Frame: Baseline, 1 month, 3 months, 6 months, and 12 months
|
The Activities of Daily Living assessment comprised three questions about the effects of back pain or back problems over the previous 2-week period.
The patient was asked if they had cut down on usual activities, the number of days in which the patient had cut down on usual activities and the number of days that the patient had spent at least half a day in bed because of back pain or back problems.
|
Baseline, 1 month, 3 months, 6 months, and 12 months
|
Ambulatory Status Change From Baseline to One Month
Time Frame: 1 month
|
Ambulatory status was assessed using a three-category system, fully ambulatory, ambulatory with assistance, or not ambulatory.
|
1 month
|
Ambulatory Status Change
Time Frame: Baseline, 7 days, 1 month, 3 months, 6 months, and 12 months
|
Ambulatory status was assessed using a three-category system, fully ambulatory, ambulatory with assistance, or not ambulatory.
|
Baseline, 7 days, 1 month, 3 months, 6 months, and 12 months
|
Index Spinal Deformity Change Measured by Index Vertebral Body Angles From Baseline to 1 Month
Time Frame: Baseline and 1 month
|
Index spinal deformity was measured by Kyphotic angle, local Cobb angle, thoracic and lumbar Cobb angle, and anterior, middle and posterior vertebral body heights for each index VCF.
|
Baseline and 1 month
|
Index Spinal Deformity Change Measured by Index Vertebral Body Angles
Time Frame: Baseline, post-operation, 1 month, and 12 months
|
Index spinal deformity was measured by Kyphotic angle, local Cobb angle, thoracic and lumbar Cobb angle, and anterior, middle and posterior vertebral body heights for each index VCF.
|
Baseline, post-operation, 1 month, and 12 months
|
Index Spinal Deformity Change Measured by Index Vertebral Body Height Ratio
Time Frame: Baseline and 1 month
|
Index spinal deformity was measured by Kyphotic angle, local Cobb angle, thoracic and lumbar Cobb angle, and anterior, middle and posterior vertebral body heights for each index VCF.
Index Vertebral Body Height Ratio (VBHR) was defined as index vertebra height divided by the average of normal superior and inferior adjacent vertebrae.
|
Baseline and 1 month
|
Index Spinal Deformity Change Measured by Index Vertebral Body Height Ratio
Time Frame: Baseline, post-operation, 1 month, and 12 months
|
Index spinal deformity was measured by Kyphotic angle, local Cobb angle, thoracic and lumbar Cobb angle, and anterior, middle and posterior vertebral body heights for each index VCF.
Index Vertebral Body Height Ratio (VBHR) was defined as index vertebra height divided by the average of normal superior and inferior adjacent vertebrae.
|
Baseline, post-operation, 1 month, and 12 months
|
Back Pain Analgesics Used
Time Frame: Baseline, 7 days, and 1 month
|
Baseline, 7 days, and 1 month
|
|
Back Pain Analgesics Used
Time Frame: Baseline, 7 days, 1 month, 3 months, 6 months, and 12 months
|
Baseline, 7 days, 1 month, 3 months, 6 months, and 12 months
|
|
Change in Neurology Status From Baseline (Motor Strength)
Time Frame: 1 month
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain. Evaluation criteria of motor strength (scored 0-5) for rectus abdominis, hip extensors and flexors, knee extensors and flexors, and foot plantar and dorsiflexors as following: absent voluntary contraction = 0, contractions unable to move joint = 1, movement with gravity eliminated = 2, movement against gravity = 3, movement against resistance = 4, full strength = 5 |
1 month
|
Change in Neurology Status From Baseline (Motor Strength)-Per Protocol
Time Frame: 1 month, 3 months, 6 months, and 12 months
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain. Evaluation criteria of motor strength (scored 0-5) for rectus abdominis, hip extensors and flexors, knee extensors and flexors, and foot plantar and dorsiflexors as following: absent voluntary contraction = 0, contractions unable to move joint = 1, movement with gravity eliminated = 2, movement against gravity = 3, movement against resistance = 4, full strength = 5 |
1 month, 3 months, 6 months, and 12 months
|
Change in Neurological Status From Baseline (Sensory Examination)
Time Frame: 1 month
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain.
For sensory examination, the Investigator assessed sensory status at baseline and a change from baseline beginning with the most cephalad index level treated through L5.
|
1 month
|
Change in Neurological Status From Baseline (Sensory Examination)
Time Frame: 1 months, 3 months, 6 months, and 12 months
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain.
For sensory examination, the Investigator assessed sensory status at baseline and a change from baseline beginning with the most cephalad index level treated through L5.
|
1 months, 3 months, 6 months, and 12 months
|
Change in Neurological Status From Baseline (Reflex Strength)
Time Frame: 1 month
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain. Evaluation criteria of reflexes (scored 0-3) for patellar and Achilles reflexes as following: absent = 0, hypoactive = 1, normal = 2, brisk or clonus = 3 |
1 month
|
Change in Neurological Status From Baseline (Reflex Strength)
Time Frame: 1 months, 3 months, 6 months, and 12 months
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain. Evaluation criteria of reflexes (scored 0-3) for patellar and Achilles reflexes as following: absent = 0, hypoactive = 1, normal = 2, brisk or clonus = 3 |
1 months, 3 months, 6 months, and 12 months
|
Change in Neurological Status From Baseline (Limb Strength)
Time Frame: 1 month
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain.
Radicular lower limb pain was assessed the presence of paresthesia, weakness, and/or painful straight leg raising (SLR).
|
1 month
|
Change in Neurological Status From Baseline (Limb Strength)
Time Frame: 1 months, 3 months, 6 months, and 12 months
|
The neurological examination included motor strength, sensory examination, reflexes below the level of the most cephalad index vertebral body fracture, and the presence of radicular pain.
Radicular lower limb pain was assessed the presence of paresthesia, weakness, and/or painful straight leg raising (SLR).
|
1 months, 3 months, 6 months, and 12 months
|
Rate of Study Treatment-related Adverse Events Within 30 Days of Baseline
Time Frame: 1 month
|
The study treatment-related AEs were defined as follows:
|
1 month
|
Rate of Study Treatment-related Adverse Events Till Study Completion
Time Frame: 12 months
|
The study treatment-related AEs were defined as follows:
|
12 months
|
Rate of Subsequent Vertebral Body Fractures
Time Frame: 1 month
|
1 month
|
|
Rate of Subsequent Vertebral Body Fractures
Time Frame: 1 month and 12 months
|
Based on patients with at least 7 analyzable vertebrae.
|
1 month and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: James Berenson, M.D., Institute for Myeloma & Bone Cancer Research
- Principal Investigator: Frank Vrionis, M.D., H. Lee Moffitt Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP0401 - CAFE Study
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Balloon Kyphoplasty
-
University of California, San FranciscoMedtronics, Inc.CompletedMultiple MyelomaUnited States
-
Medtronic Spine LLCCompletedMultiple Myeloma | Bone Neoplasms | Osteoporosis | OsteopeniaUnited States
-
Mayo ClinicCompleted
-
Centre Leon BerardTerminatedSolid Tumors | Spine MetastasisFrance
-
Assistance Publique - Hôpitaux de ParisTerminatedMultiple Myeloma | Vertebral Fracture | Osteolytic MetastasesFrance
-
Stryker InstrumentsTalosixActive, not recruiting
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompletedSPINAL FractureFrance
-
Synthes GmbHCompletedVertebral Body FracturesGermany, Austria
-
Vexim SAACES Ing.-GmbHCompletedOsteoporosis | Spinal Fractures | Back Injuries | Vertebral Compression FracturesSpain, France, Switzerland, Germany, Italy
-
University Hospital TuebingenUnknown